Welcome to our dedicated page for IDEXX Laboratories news (Ticker: IDXX), a resource for investors and traders seeking the latest updates and insights on IDEXX Laboratories stock.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) is frequently in the news as a global company focused on pet healthcare innovation, veterinary diagnostics, and software. News about IDEXX often highlights product launches, diagnostic advances, financial results, and corporate governance updates, reflecting its role in companion animal care, livestock and dairy health, and water safety.
Recent announcements include new diagnostic imaging and cancer testing capabilities. IDEXX has introduced the Vue DR50 Plus Digital Imaging System, described as its most advanced diagnostic imaging solution for veterinary practices, combining high-definition, AI-powered imaging with lower radiation doses compared with earlier IDEXX systems and other veterinary imaging solutions. The company has also reported expansions of its IDEXX Cancer Dx Panel and applications on the inVue Dx Cellular Analyzer, aimed at providing earlier insights and rapid, in-clinic answers for canine cancer cases.
Investors and veterinary professionals following IDXX news will also encounter quarterly earnings releases, where IDEXX discusses revenue growth, earnings per share, and performance across areas such as the Companion Animal Group, Water, and Livestock, Poultry and Dairy. Additional news items cover topics like CEO succession planning, board appointments, and participation in investor conferences.
This news page aggregates these types of updates so readers can review IDEXX’s latest disclosures on diagnostics, software, AI-enabled tools, telemedicine services, and financial performance. For anyone tracking IDXX stock, veterinary sector developments, or advances in animal health diagnostics, this feed provides a centralized view of the company’s publicly reported developments over time.
IDEXX Laboratories, a leading veterinary diagnostics company, will release its 2021 second quarter financial results on July 30, 2021, before market opening. The accompanying analyst conference call is scheduled for 8:30 a.m. ET on the same day. Interested parties can access a live webcast at www.idexx.com/investors or join via telephone by dialing 1-888-771-4371 or 1-847-585-4405 with access code 50183464. An archived version of the call will be available after 1:00 p.m. ET and remain accessible for one year.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) has acquired ezyVet®, a leading cloud-based practice information management system. This strategic acquisition enhances IDEXX's portfolio, allowing the company to offer comprehensive cloud software solutions that improve veterinary practice efficiency and care standards. The acquisition includes Vet Radar, an innovative electronic treatment sheet solution. IDEXX aims to leverage ezyVet's technology to enhance customer satisfaction and support veterinarians in their business growth.
IDEXX Laboratories (NASDAQ: IDXX) will participate in the Stifel Virtual Jaws & Paws Conference on June 2, 2021, at 10:00 am (EDT). CEO Jay Mazelsky and CFO Brian McKeon will engage in a virtual fireside chat. Investors can access the live audio webcast on the IDEXX website, with an archived version available later. Additionally, IDEXX will host its 2021 Virtual Investor Day on August 12, 2021, starting at 10:00 am (EDT). Further details will be announced closer to the date.
IDEXX Laboratories reported strong first quarter results for 2021, with revenues of $778 million, marking a 24% increase and 21% organic growth. Companion Animal Group (CAG) Diagnostics drove this growth, showing a 27% increase in recurring revenue. EPS rose to $2.35, an 82% growth. The company raised its 2021 revenue guidance to between $3,105 million and $3,160 million. Additionally, IDEXX's operating margins improved significantly, reflecting robust demand for its diagnostics products. However, water revenue saw a modest decline of 3% organically.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) has announced the release date for its first quarter financial results, which is set for May 4, 2021, prior to market opening. An analyst conference call will occur at 8:30 a.m. ET on the same day. Interested parties may access the call via a live webcast on the IDEXX investor website. A recorded version will be available after 1:00 p.m. ET and will remain accessible for one year. IDEXX is a leading provider of veterinary diagnostics and software, employing over 9,000 individuals globally.
IDEXX Laboratories, a leader in veterinary diagnostics, will participate in two significant virtual conferences. On February 25 at 11:45 am EST, CEO Jay Mazelsky and CFO Brian McKeon will join a fireside chat at the BofA Securities Animal Health Summit. The following week, on March 1 at 9:10 am EST, Jay Mazelsky will speak at the 42nd Annual Raymond James Institutional Investors Conference. Investors can access live presentations and archives on the IDEXX website.
IDEXX Laboratories reported strong fourth quarter results with 19% revenue growth, driven by a 23% increase in CAG Diagnostics recurring revenue. The company's full-year EPS rose to $6.71, a 37% increase on a reported basis. For 2021, IDEXX forecasts revenue of $3,065M - $3,120M and EPS between $7.39 and $7.71, indicating growth of 10% - 14%. The 2020 performance was supported by operating margin improvements and strong market demand in companion animal healthcare. However, growth was moderated by COVID-19 impacts on new instrument placements.
IDEXX Laboratories (NASDAQ: IDXX) announced a landmark initiative to support Tuskegee University College of Veterinary Medicine (TUCVM) with a $3.6 million contribution over six years. This initiative includes nine full scholarships, mental health support, and emergency funding to enhance diversity, equity, and inclusion in veterinary medicine. TUCVM, the only veterinary program at a Historically Black College, has educated 70% of African American veterinarians. IDEXX emphasizes the importance of diverse veterinary care to meet the needs of a growing pet-owning population.
IDEXX Laboratories, a leader in veterinary diagnostics, has announced the release of its 2020 fourth quarter and full-year financial results on February 2, 2021.
Results will be available before the market opens, followed by an analyst conference call at 8:30 a.m. ET. Investors can access the live webcast and a recorded edition afterward via the IDEXX investor relations website.
IDEXX is known for its innovative diagnostic and software products that enhance veterinary services and improve operational efficiency in practices globally.
IDEXX Laboratories (NASDAQ: IDXX) has appointed Dr. Asha S. Collins, the Head of U.S. Clinical Operations at Genentech, to its Board of Directors, effective November 11, 2020. Larry Kingsley, Board Chair, stated that Dr. Collins brings valuable scientific and strategic experience. Dr. Collins expressed her enthusiasm to contribute to IDEXX's mission of enhancing health and well-being across sectors. Her background includes leadership roles at McKesson Corporation and Quintiles. IDEXX is a leader in veterinary diagnostics and healthcare innovation, employing over 9,000 individuals globally.